SCHEDULE 13G/A: Ayrton Capital and Affiliates Report 9.9% Passive Stake in Ocean Biomedical

Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri have jointly reported a 9.9% beneficial ownership stake in Ocean Biomedical, Inc. as of December 31, 2024.

Summary

• Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Ocean Biomedical, Inc.
• As of December 31, 2024, the Reporting Persons collectively beneficially own 3,873,632 shares of Ocean Biomedical, Inc. Common Stock.
• This ownership represents 9.9% of the Issuer's outstanding Common Stock.
• The reported shares include 3,873,632 shares of Common Stock issuable upon the exercise of certain warrants and conversion of a convertible note held by the Reporting Persons.
• The issuable shares are subject to a 9.99% beneficial ownership blocker.
• The percentage of class is calculated based on 34,868,628 shares of Common Stock outstanding as of December 20, 2024, as stated in the Issuer's Form 10-Q filed on December 23, 2024.
• Each Reporting Person holds sole voting and sole dispositive power over 3,873,632 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This is a routine Schedule 13G filing indicating a passive beneficial ownership stake, which is generally neutral in sentiment. It does not contain information that would significantly alter the company's operational or financial outlook.

Positives

• The disclosure of a significant 9.9% passive stake by institutional investors like Alto Opportunity Master Fund, managed by Ayrton Capital LLC, may signal confidence in Ocean Biomedical, Inc. from these entities.

Future Outlook

NA

Industry Context

This Schedule 13G filing is a routine disclosure of a passive investment stake and does not provide specific insights into broader industry trends or competitive dynamics for Ocean Biomedical, Inc. It primarily reflects an investment decision by the reporting entities.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive investment by institutional entities may provide some level of confidence or signal continued institutional interest in Ocean Biomedical, Inc.

Key Dates

Keywords

Ocean Biomedical, Ayrton Capital, Alto Opportunity Master Fund, Waqas Khatri, Schedule 13G, beneficial ownership, common stock, passive investment, equity stake, SEC filing